Nelson Dusetti: A Paradigm Shift in How We View Pancreatic Ductal Adenocarcinoma
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn about a paper he co-authored with colleagues published in Translational Oncology:
“New publication out!
Pleased to share our latest review from the Pancreatic Cancer Team, just published in Translational Oncology.
‘Understanding the heterogeneity of pancreatic ductal adenocarcinoma’
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and treatment-resistant cancers. In this review, we propose a paradigm shift: PDAC should no longer be seen as composed of fixed subtypes, but rather as a phenotypic continuum shaped by epigenetic plasticity and microenvironmental signals.
This evolving view has important implications for developing new therapeutic strategies that better address tumor adaptation and resistance.
This article is the result of a long-standing and fruitful collaboration between the CRCM – Marseille Cancer Research Center – Paoli-Calmettes Institute and the Medical College of Wisconsin (Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine), a partnership that has endured for many years and one we are proud to continue.
Many thanks to Juan Iovanna, Nicolas Fraunhoffer, and Raul Urrutia for this shared effort.”
Title: Understanding the heterogeneity of pancreatic ductal adenocarcinoma
Authors: Juan Iovanna, Nicolas Fraunhoffer, Raul Urrutia, Nelson Dusetti
You can read the Full Article in Translational Oncology.
More posts featuring Nelson Dusetti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023